Trial Profile

A Phase 1, Open-label, Dose Escalation Study of Oprozomib Administered Orally in Patients With Advanced Refractory or Recurrent Solid Tumors

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 04 May 2017

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Oprozomib (Primary)
Indications Solid tumours
Focus Adverse reactions; First in man; Pharmacokinetics
Sponsors Onyx Pharmaceuticals

Most Recent Events

22 Aug 2012 Status changed from active, no longer recruiting to recruiting as reported by ClinicalTrials.gov.
22 Aug 2012 Planned end date changed from 1 Jul 2011 to 1 Dec 2012 as reported by ClinicalTrials.gov.
06 Jun 2012 Interim results have been reported at ASCO 2012.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com